Mechanism of Action
SERCA Inhibition
Myoregulin is a 46-amino acid single-pass transmembrane micropeptide that integrates into the sarcoplasmic reticulum (SR) membrane of skeletal muscle. It interacts with SERCA2a pump proteins through its transmembrane domain, reducing SERCA ATPase activity and slowing cytoplasmic calcium reuptake. This prolongs calcium transients in the cytoplasm following excitation-contraction coupling.
Micropeptide Family Context
Myoregulin belongs to a family of transmembrane SERCA regulatory micropeptides that includes phospholamban (cardiac muscle, PLN) and sarcolipin (atrial/skeletal muscle, SLN). These peptides all inhibit SERCA through a similar mechanism but have distinct tissue expression patterns. The discovery of this micropeptide family revealed a new paradigm of gene regulation in which small ORFs within non-coding RNA species encode physiologically important proteins.
Research Summary
Exercise Performance
PreclinicalMyoregulin knockout mice show enhanced skeletal muscle contractile performance, faster calcium transient kinetics, and improved exercise capacity compared to wild-type animals. These mice show greater endurance and sprint capacity. These findings identified myoregulin as a negative regulator of muscle performance and a potential therapeutic target for muscle diseases.
Muscle Disease Applications
PreclinicalMyoregulin silencing using antisense oligonucleotides or shRNA in mouse models of Duchenne muscular dystrophy (DMD) and aging-related sarcopenia shows partial restoration of muscle function. By disinhibiting SERCA, MLN knockdown may benefit conditions where calcium handling in muscle is impaired.
Calculate your Myoregulin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| SERCA activity assay | N/A (knockdown model) | N/A | Genetic knockout/knockdown |
| Exercise performance | MLN-KO mice | N/A | Genetic model |
No pharmacological agent targets myoregulin clinically. Research uses genetic models.
Interactions
Safety Profile
Myoregulin is an endogenous muscle-embedded micropeptide; no exogenous administration data exists. Myoregulin deletion in mice is well tolerated with enhanced rather than impaired muscle phenotype. Therapeutic targeting via antisense oligonucleotides is being explored for muscle diseases; safety of chronic knockdown requires investigation.
References
- [1]Anderson DM et al. (2015). A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell, 160(4), 595-606.
- [2]Makarewich CA and Olson EN (2017). Mining for micropeptides. Trends in Cell Biology, 27(9), 685-696.